Seasoned Life Sciences Team Launches Ignyte Bio To Speed Therapeutics Discovery
Seattle biomaterials company specializes in human immune cell products and biopharma consulting services
SEATTLE--(BUSINESS WIRE)--Spurred by the pharmaceutical industry’s demand for immune cells for specialized therapeutic research, four biomaterials leaders have launched Ignyte Bio. The leadership team has a combined 105 years of experience developing complex cells for leading biopharma companies, crafting custom products for academic research, and generating high-volume biomaterials for manufacturers and contract research organizations (CROs).
Ignyte Bio sells well-characterized immune cell products and develops custom products for biopharma customers across the globe. The company also offers consulting services, such as assay development and study design.
“As scientists, we understand the cost of delayed milestones and cost overruns,” said Ponni Anand, CEO of Ignyte Bio. “By partnering with Ignyte Bio, biopharma companies can spend less time sourcing custom-developed materials, and more time on discovery and innovation.”
The leadership team was the driving force behind Astarte Biologics in Bothell, WA which successfully exited in 2020.
“Scientists founded Ignyte Bio so life sciences companies can innovate, develop, and customize therapies easily,” said Ben Tjoa, Ph.D, chief scientific officer at Ignyte Bio. “Working with Ignyte Bio is like having a virtual scientist at your side for biomaterials, assay development, and consulting services.”
Ignyte Bio plans to double its workforce in Washington over the next year.
About Ignyte Bio
Ignyte Bio believes that while biopharma research is complex, biosourcing shouldn’t be. The company provides human immune cells, along with custom development and consulting services. Its scientists have decades of experience solving complex biomaterial and product development challenges for leading biopharma companies, CROs, and academic research institutions. For more information, visit www.ignytebio.com.